查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1848367

全球微生物组疗法市场：预测至 2032 年—按疗法类型、适应症、给药途径、最终用户和地区分類的分析

Microbiome Therapeutics Market Forecasts to 2032 - Global Analysis By Therapeutic Type, Indication, Delivery Modes, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2025 年，全球微生物组疗法市场规模将达到 2,456 亿美元，到 2032 年将达到 2,2593 亿美元，预测期内复合年增长率为 37.3%。

微生物组疗法是指一系列旨在调节或修復人体微生物组（存在于体内外的复杂微生物群落）以改善健康或治疗疾病的治疗方法方法。这些治疗方法针对肠道、皮肤和其他微生物环境，以纠正与发炎性肠道疾病、肥胖、代谢紊乱和感染疾病等相关的失衡。治疗方法包括益生菌、益生元、合益素、粪便微生物移植和新一代活体生物疗法。透过影响微生物的组成和功能，微生物组疗法旨在以精准且个人化的方式增强免疫力、代谢功能和整体健康。

胃肠道疾病发生率上升

医疗保健机构正在探索治疗级配方，以应对肠躁症（IBS）、克隆氏症和溃疡性大肠炎等疾病。研究实验室正在检验菌株特异性抑制发炎和修復肠道屏障的功效。生物技术公司与临床网路之间的伙伴关係正在加速产品开发。监管机构正在支持对高需求适应症进行快速核准。市场正朝向针对特定疾病的微生物组疗法转变。

高昂的研发成本

微生物组疗法的临床试验需要耗时较长、通讯协定复杂且需要专门的基础设施。活体生物疗法的生产需要严格的品管和低温运输物流。中小企业面临资金短缺和监管障碍。由于菌株变异性和製剂复杂性，智慧财产权保护仍面临挑战。这些限制因素阻碍了企业进入市场和产品多样化。

消费者转向预防性护理

人们正在寻求非侵入性方法来改善免疫力、消化和代谢健康。治疗级益生菌和益生元在临床和医疗保健领域正日益受到重视。与个人化营养平台的整合正在增强其相关性和用户参与。零售和数位健康通路正在扩大微生物组产品的可近性。这种趋势正在重新定义治疗和预防保健之间的界限。

临床证据有限，不足以广泛应用

许多微生物组疗法缺乏在不同人群中进行的广泛同行评审检验。菌株性能和宿主反应的差异性使标准化变得复杂。缺乏统一的指引也延缓了其融入主流治疗方案的进程。支付方和医疗服务提供者对报销和长期疗效仍持谨慎态度。这些不足之处凸显了加强临床框架和上市后监测的必要性。

新冠疫情的影响：

新冠疫情凸显了肠道环境在免疫和復原中的重要作用，推动了人们对微生物组疗法的兴趣。针对新冠后遗症发炎和长期症状的研究加速了标靶製剂的研发。医院和健康机构扩大了益生菌和益生元的使用，以增强免疫力。供应链中断曾一度影响了原料可得性和低温运输物流。疫情后的復苏工作正在推动可规模化生产、保质期长的微生物组产品的投资。这场危机已将微生物组健康从一个边缘问题提升为一项策略重点。

预计在预测期内，益生元和益生菌（治疗级）细分市场将成为最大的细分市场。

由于其临床相关性、安全性以及扩充性，益生元和益生菌（治疗级）预计将在预测期内占据最大的市场份额。这些製剂用于治疗胃肠道、代谢和免疫相关疾病。医院和专科诊所正将其纳入慢性病和急性病的治疗通讯协定中。供应商正在优化菌株组合和给药方式，以实现标靶疗效。监管部门的核准和消费者的信任正在巩固该领域的领先地位。这一类别为微生物组疗法的商业性化奠定了基础。

预计在预测期内，活体生物治疗产品（LBP）细分市场将实现最高的复合年增长率。

随着精准微生物组工程的蓬勃发展，预计在预测期内，活体生物治疗产品（LBP）领域将达到最高成长率。这些治疗方法利用经过基因鑑定的细菌菌株，旨在达到特定的临床疗效。粪便微生物移植和合成菌丛的研究正在扩大治疗范围。生物技术公司正在开发能够确保活性并靶向定植的递送系统。对符合GMP规范的生产和监管合规性的投资正在加速临床应用。

占比最大的地区：

在预测期内，北美预计将占据最大的市场份额，这主要得益于其先进的研究生态系统、完善的监管体系和较高的消费者认知度。美国和加拿大正在学术界、临床界和商业界等多个领域拓展微生物组临床试验。对生物技术新兴企业和转化研究的投资正在推动创新。领先的益生菌生产商和数位健康平台的存在进一步增强了市场实力。完善的医保报销机制和临床指引正在推动治疗方法的普及应用。该地区将继续引领微生物组商业化的发展。

复合年增长率最高的地区：

预计亚太地区在预测期内将实现最高的复合年增长率，这主要得益于医疗保健服务可近性的提高、健康需求的成长以及研发投入的增加。中国、日本、韩国和印度等国家正在临床和消费领域拓展微生物组倡议。政府支持的健康项目和新兴企业生态系统正在加速产品开发。本土製造商正在推出符合当地文化特色的配方和给药方式。人们对肠道健康和预防性医疗保健日益增长的兴趣正在推动各个年龄层对相关产品的接受度。

免费客製化服务

订阅本报告的用户可从以下免费自订选项中选择一项：

  • 公司简介
    • 对最多三家其他公司进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家进行市场估算、预测和复合年增长率分析（註：基于可行性检查）
  • 竞争基准化分析
    • 基于产品系列、地域覆盖和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 引言

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 分析方法
  • 分析材料
    • 原始研究资料
    • 二手研究资讯来源
    • 先决条件

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 市场机会
  • 威胁
  • 终端用户分析
  • 新兴市场
  • 感染疾病疫情的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代产品的威胁
  • 新参与企业的威胁
  • 公司间的竞争

5. 全球微生物组疗法市场（依疗法类型划分）

  • 活体生物製药公司（LBP）
  • 微生物组来源的小分子
  • 益生元与益生菌（治疗级）
  • 后生元
  • 噬菌体疗法
  • 粪便微生物移植（FMT）
  • 其他治疗方法

6. 全球微生物组疗法市场（依适应症划分）

  • 胃肠道疾病
  • 代谢紊乱
  • 肿瘤和免疫疗法调控
  • 神经系统和精神疾病
  • 皮肤病
  • 感染疾病
  • 女性健康
  • 其他迹象

7. 全球微生物组疗法市场依给药方式划分

  • 口服胶囊
  • 液体和悬浮液
  • 直肠/灌肠剂型
  • 注射剂
  • 其他配送方式

8. 全球微生物组疗法市场（以最终用户划分）

  • 医院和专科诊所
  • 研究所
  • 生物技术和製药公司
  • CDMO（合约开发和生产组织）
  • 学术医疗中心
  • 其他最终用户

9. 全球微生物组疗法市场（按地区划分）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：主要趋势

  • 合约、商业伙伴关係和合资企业
  • 企业合併（M&A）
  • 新产品上市
  • 业务拓展
  • 其他关键策略

第十一章 企业概况

  • Seres Therapeutics
  • Finch Therapeutics Group
  • Vedanta Biosciences
  • Rebiotix Inc.
  • 4D Pharma plc
  • Evelo Biosciences
  • Second Genome
  • Symbiome Inc.
  • BiomX Inc.
  • Axial Therapeutics
  • Kaleido Biosciences
  • DayTwo
  • Viome Life Sciences
  • LNC Therapeutics
  • Pendulum Therapeutics
Product Code: SMRC31567

According to Stratistics MRC, the Global Microbiome Therapeutics Market is accounted for $245.6 billion in 2025 and is expected to reach $2259.3 billion by 2032 growing at a CAGR of 37.3% during the forecast period. Microbiome therapeutics refers to a class of medical treatments designed to modulate or restore the human microbiome-the complex community of microorganisms residing in and on the body-to improve health or treat disease. These therapies target the gut, skin, or other microbial environments to correct imbalances linked to conditions such as inflammatory bowel disease, obesity, metabolic disorders, and infections. Approaches include probiotics, prebiotics, synbiotics, fecal microbiota transplantation, and next-generation live biotherapeutics. By influencing microbial composition and function, microbiome therapeutics aim to enhance immunity, metabolism, and overall well-being in a precise, personalized manner.

Market Dynamics:

Driver:

Rising prevalence of gastrointestinal disorders

Healthcare providers are exploring therapeutic-grade formulations to address conditions such as IBS, Crohn's disease, and ulcerative colitis. Research institutions are validating strain-specific efficacy for inflammation control and gut barrier restoration. Partnerships between biotech firms and clinical networks are accelerating product development. Regulatory bodies are supporting fast-track approvals for high-need indications. The market is shifting toward condition-specific microbiome therapies.

Restraint:

High research and development costs

Clinical trials for microbiome therapeutics require long timelines, complex protocols, and specialized infrastructure. Manufacturing live biotherapeutics demands stringent quality control and cold-chain logistics. Small and mid-sized players face funding gaps and regulatory hurdles. Intellectual property protection remains challenging due to strain variability and formulation complexity. These constraints are slowing market entry and product diversification.

Opportunity:

Consumer shift towards preventive healthcare

Individuals are seeking non-invasive solutions to improve immunity, digestion, and metabolic health. Therapeutic-grade probiotics and prebiotics are gaining traction in clinical and wellness settings. Integration with personalized nutrition platforms is enhancing relevance and engagement. Retail and digital health channels are broadening access to microbiome-based products. This momentum is redefining the boundary between therapeutic and preventive care.

Threat:

Limited clinical evidence for broad applications

Many microbiome therapies lack large-scale, peer-reviewed validation across diverse populations. Variability in strain performance and host response complicates standardization. Absence of harmonized guidelines is slowing integration into mainstream treatment protocols. Payers and providers remain cautious about reimbursement and long-term efficacy. These gaps are prompting calls for stronger clinical frameworks and post-market surveillance.

Covid-19 Impact:

The pandemic highlighted the role of gut health in immunity and recovery, boosting interest in microbiome therapeutics. Research into post-Covid inflammation and long-haul symptoms accelerated development of targeted formulations. Hospitals and wellness providers expanded use of probiotics and prebiotics to support immune resilience. Supply chain disruptions temporarily affected raw material availability and cold-chain logistics. Recovery efforts are driving investment in scalable, shelf-stable microbiome products. The crisis elevated microbiome health from niche interest to strategic priority.

The prebiotics & probiotics (Therapeutic-Grade) segment is expected to be the largest during the forecast period

The prebiotics & probiotics (Therapeutic-Grade) segment is expected to account for the largest market share during the forecast period due to their clinical relevance, safety profile, and scalability. These formulations are being used to manage gastrointestinal, metabolic, and immune-related conditions. Hospitals and specialty clinics are integrating them into treatment protocols for chronic and acute disorders. Vendors are optimizing strain combinations and delivery formats for targeted efficacy. Regulatory approvals and consumer trust are reinforcing segment dominance. This category anchors the commercial foundation of microbiome therapeutics.

The live biotherapeutic products (LBPs) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the live biotherapeutic products (LBPs) segment is predicted to witness the highest growth rate as precision microbiome engineering gains momentum. These therapies involve genetically characterized strains designed for specific clinical outcomes. Research into fecal microbiota transplantation and synthetic consortia is expanding therapeutic scope. Biotech firms are developing delivery systems that ensure viability and targeted colonization. Investment in GMP manufacturing and regulatory alignment is accelerating clinical translation.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced research ecosystem, regulatory support, and consumer awareness. The United States and Canada are scaling microbiome trials across academic, clinical, and commercial settings. Investment in biotech startups and translational research is driving innovation. Presence of leading probiotic manufacturers and digital health platforms is reinforcing market strength. Reimbursement pathways and clinical guidelines are supporting therapeutic adoption. The region remains the benchmark for microbiome commercialization.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare access, wellness demand, and research investment expand. Countries like China, Japan, South Korea, and India are scaling microbiome initiatives across clinical and consumer domains. Government-backed health programs and startup ecosystems are accelerating product development. Local manufacturers are launching culturally tailored formulations and delivery formats. Rising interest in gut health and preventive care is boosting adoption across demographics.

Key players in the market

Some of the key players in Microbiome Therapeutics Market include Seres Therapeutics, Finch Therapeutics Group, Vedanta Biosciences, Rebiotix Inc., 4D Pharma plc, Evelo Biosciences, Second Genome, Symbiome Inc., BiomX Inc., Axial Therapeutics, Kaleido Biosciences, DayTwo, Viome Life Sciences, LNC Therapeutics and Pendulum Therapeutics.

Key Developments:

In June 2024, Seres Therapeutics entered into a Memorandum of Understanding with Nestle Health Science for the sale of its microbiome therapeutic, VOWST. The transaction was finalized, with Nestle acquiring full ownership of VOWST, including all related intellectual property rights.

In March 2022, 4D Pharma entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. This partnership aimed to evaluate the combination of 4D Pharma's lead immuno-oncology candidate, MRx0518, with Merck's anti-PD-L1 antibody, avelumab, in patients with advanced solid tumors.

Therapeutic Types Covered:

  • Live Biotherapeutic Products (LBPs)
  • Microbiome-Derived Small Molecules
  • Prebiotics & Probiotics (Therapeutic-Grade)
  • Postbiotics
  • Phage Therapy
  • Fecal Microbiota Transplantation (FMT)
  • Other Therapeutic Types

Indications Covered:

  • Gastrointestinal Disorders
  • Metabolic Disorders
  • Oncology & Immunotherapy Modulation
  • Neurological & Psychiatric Conditions
  • Skin Disorders
  • Infectious Diseases
  • Women's Health
  • Other Indications

Delivery Modes Covered:

  • Oral Capsules
  • Liquids & Suspensions
  • Rectal/Enema Formulations
  • Injectable Formats
  • Other Delivery Modes

End Users Covered:

  • Hospitals & Specialty Clinics
  • Research Institutes
  • Biotech & Pharmaceutical Companies
  • Contract Development & Manufacturing Organizations (CDMOs)
  • Academic Medical Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Microbiome Therapeutics Market, By Therapeutic Type

  • 5.1 Introduction
  • 5.2 Live Biotherapeutic Products (LBPs)
  • 5.3 Microbiome-Derived Small Molecules
  • 5.4 Prebiotics & Probiotics (Therapeutic-Grade)
  • 5.5 Postbiotics
  • 5.6 Phage Therapy
  • 5.7 Fecal Microbiota Transplantation (FMT)
  • 5.8 Other Therapeutic Types

6 Global Microbiome Therapeutics Market, By Indication

  • 6.1 Introduction
  • 6.2 Gastrointestinal Disorders
  • 6.3 Metabolic Disorders
  • 6.4 Oncology & Immunotherapy Modulation
  • 6.5 Neurological & Psychiatric Conditions
  • 6.6 Skin Disorders
  • 6.7 Infectious Diseases
  • 6.8 Women's Health
  • 6.9 Other Indications

7 Global Microbiome Therapeutics Market, By Delivery Mode

  • 7.1 Introduction
  • 7.2 Oral Capsules
  • 7.3 Liquids & Suspensions
  • 7.4 Rectal/Enema Formulations
  • 7.5 Injectable Formats
  • 7.6 Other Delivery Modes

8 Global Microbiome Therapeutics Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Specialty Clinics
  • 8.3 Research Institutes
  • 8.4 Biotech & Pharmaceutical Companies
  • 8.5 Contract Development & Manufacturing Organizations (CDMOs)
  • 8.6 Academic Medical Centers
  • 8.7 Other End Users

9 Global Microbiome Therapeutics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Seres Therapeutics
  • 11.2 Finch Therapeutics Group
  • 11.3 Vedanta Biosciences
  • 11.4 Rebiotix Inc.
  • 11.5 4D Pharma plc
  • 11.6 Evelo Biosciences
  • 11.7 Second Genome
  • 11.8 Symbiome Inc.
  • 11.9 BiomX Inc.
  • 11.10 Axial Therapeutics
  • 11.11 Kaleido Biosciences
  • 11.12 DayTwo
  • 11.13 Viome Life Sciences
  • 11.14 LNC Therapeutics
  • 11.15 Pendulum Therapeutics

List of Tables

  • Table 1 Global Microbiome Therapeutics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Microbiome Therapeutics Market Outlook, By Therapeutic Type (2024-2032) ($MN)
  • Table 3 Global Microbiome Therapeutics Market Outlook, By Live Biotherapeutic Products (LBPs) (2024-2032) ($MN)
  • Table 4 Global Microbiome Therapeutics Market Outlook, By Microbiome-Derived Small Molecules (2024-2032) ($MN)
  • Table 5 Global Microbiome Therapeutics Market Outlook, By Prebiotics & Probiotics (Therapeutic-Grade) (2024-2032) ($MN)
  • Table 6 Global Microbiome Therapeutics Market Outlook, By Postbiotics (2024-2032) ($MN)
  • Table 7 Global Microbiome Therapeutics Market Outlook, By Phage Therapy (2024-2032) ($MN)
  • Table 8 Global Microbiome Therapeutics Market Outlook, By Fecal Microbiota Transplantation (FMT) (2024-2032) ($MN)
  • Table 9 Global Microbiome Therapeutics Market Outlook, By Other Therapeutic Types (2024-2032) ($MN)
  • Table 10 Global Microbiome Therapeutics Market Outlook, By Indication (2024-2032) ($MN)
  • Table 11 Global Microbiome Therapeutics Market Outlook, By Gastrointestinal Disorders (2024-2032) ($MN)
  • Table 12 Global Microbiome Therapeutics Market Outlook, By Metabolic Disorders (2024-2032) ($MN)
  • Table 13 Global Microbiome Therapeutics Market Outlook, By Oncology & Immunotherapy Modulation (2024-2032) ($MN)
  • Table 14 Global Microbiome Therapeutics Market Outlook, By Neurological & Psychiatric Conditions (2024-2032) ($MN)
  • Table 15 Global Microbiome Therapeutics Market Outlook, By Skin Disorders (2024-2032) ($MN)
  • Table 16 Global Microbiome Therapeutics Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 17 Global Microbiome Therapeutics Market Outlook, By Women's Health (2024-2032) ($MN)
  • Table 18 Global Microbiome Therapeutics Market Outlook, By Other Indications (2024-2032) ($MN)
  • Table 19 Global Microbiome Therapeutics Market Outlook, By Delivery Mode (2024-2032) ($MN)
  • Table 20 Global Microbiome Therapeutics Market Outlook, By Oral Capsules (2024-2032) ($MN)
  • Table 21 Global Microbiome Therapeutics Market Outlook, By Liquids & Suspensions (2024-2032) ($MN)
  • Table 22 Global Microbiome Therapeutics Market Outlook, By Rectal/Enema Formulations (2024-2032) ($MN)
  • Table 23 Global Microbiome Therapeutics Market Outlook, By Injectable Formats (2024-2032) ($MN)
  • Table 24 Global Microbiome Therapeutics Market Outlook, By Other Delivery Modes (2024-2032) ($MN)
  • Table 25 Global Microbiome Therapeutics Market Outlook, By End User (2024-2032) ($MN)
  • Table 26 Global Microbiome Therapeutics Market Outlook, By Hospitals & Specialty Clinics (2024-2032) ($MN)
  • Table 27 Global Microbiome Therapeutics Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 28 Global Microbiome Therapeutics Market Outlook, By Biotech & Pharmaceutical Companies (2024-2032) ($MN)
  • Table 29 Global Microbiome Therapeutics Market Outlook, By Contract Development & Manufacturing Organizations (CDMOs) (2024-2032) ($MN)
  • Table 30 Global Microbiome Therapeutics Market Outlook, By Academic Medical Centers (2024-2032) ($MN)
  • Table 31 Global Microbiome Therapeutics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.